Lisa Rydén

9.2k total citations
187 papers, 5.7k citations indexed

About

Lisa Rydén is a scholar working on Cancer Research, Oncology and Genetics. According to data from OpenAlex, Lisa Rydén has authored 187 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Cancer Research, 99 papers in Oncology and 42 papers in Genetics. Recurrent topics in Lisa Rydén's work include Breast Cancer Treatment Studies (93 papers), HER2/EGFR in Cancer Research (40 papers) and Breast Lesions and Carcinomas (34 papers). Lisa Rydén is often cited by papers focused on Breast Cancer Treatment Studies (93 papers), HER2/EGFR in Cancer Research (40 papers) and Breast Lesions and Carcinomas (34 papers). Lisa Rydén collaborates with scholars based in Sweden, United States and Denmark. Lisa Rydén's co-authors include Pär‐Ola Bendahl, Mårten Fernö, Karin Jirström, Göran Landberg, Dorthe Grabau, Kristina Aaltonen, Olle Stål, Bo Nordenskjöld, Lao H. Saal and Åke Borg and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Research.

In The Last Decade

Lisa Rydén

174 papers receiving 5.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lisa Rydén Sweden 44 2.8k 2.7k 2.1k 1.1k 772 187 5.7k
Pär‐Ola Bendahl Sweden 44 3.0k 1.0× 3.3k 1.2× 2.7k 1.3× 1.4k 1.3× 928 1.2× 181 6.7k
Ja Seung Koo South Korea 43 2.8k 1.0× 2.4k 0.9× 2.7k 1.3× 807 0.8× 509 0.7× 231 6.3k
Dilip D. Giri United States 37 2.4k 0.8× 2.9k 1.1× 3.0k 1.4× 712 0.7× 728 0.9× 94 7.0k
Daniele Generali Italy 42 2.1k 0.7× 3.1k 1.2× 2.5k 1.2× 1.7k 1.6× 396 0.5× 232 6.2k
Zhi‐Ming Shao China 50 3.0k 1.1× 3.6k 1.3× 3.9k 1.9× 1.3k 1.3× 1.1k 1.4× 222 8.6k
A. Bapsi Chakravarthy United States 27 2.2k 0.8× 3.4k 1.3× 2.1k 1.0× 1.3k 1.2× 481 0.6× 69 6.3k
Hirotaka Iwase Japan 47 2.2k 0.8× 3.0k 1.1× 2.9k 1.4× 840 0.8× 1.5k 1.9× 210 6.2k
Anne F. Schott United States 32 2.5k 0.9× 4.4k 1.7× 2.4k 1.2× 898 0.8× 489 0.6× 92 7.0k
Helga B. Salvesen Norway 49 1.5k 0.5× 1.6k 0.6× 3.0k 1.4× 826 0.8× 762 1.0× 153 6.9k
Kunwei Shen China 37 2.2k 0.8× 2.7k 1.0× 1.6k 0.8× 914 0.9× 303 0.4× 231 5.2k

Countries citing papers authored by Lisa Rydén

Since Specialization
Citations

This map shows the geographic impact of Lisa Rydén's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Rydén with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Rydén more than expected).

Fields of papers citing papers by Lisa Rydén

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lisa Rydén. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Rydén. The network helps show where Lisa Rydén may publish in the future.

Co-authorship network of co-authors of Lisa Rydén

This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Rydén. A scholar is included among the top collaborators of Lisa Rydén based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Rydén. Lisa Rydén is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cronin‐Fenton, Deirdre, Signe Borgquist, Sara Alkner, et al.. (2025). Statin use and risk of breast cancer among women with benign breast disease: a Danish nationwide cohort study. British Journal of Cancer. 132(9). 828–836. 1 indexed citations
2.
Rydén, Lisa, et al.. (2025). Prognostic relevance of CD163+ immune cells in patients with metastatic breast cancer. Cancer Immunology Immunotherapy. 74(2). 42–42.
3.
4.
5.
Saal, Lao H., Niklas Loman, Yilun Chen, et al.. (2024). Monitoring ctDNA dynamics in early breast cancer using a novel ultra-sensitive tumor-informed structural variant approach combining whole-genome sequencing and multiplex dPCR.. Journal of Clinical Oncology. 42(16_suppl). 568–568. 1 indexed citations
6.
Nordenskjöld, Anna, Helena Fohlin, Johan Rosell, et al.. (2023). Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy. The Breast. 71. 63–68. 2 indexed citations
7.
Cinthio, Magnus, Stefan Kröll, Malin Malmsjö, et al.. (2023). Breast Cancer Diagnosis Using Extended-Wavelength–Diffuse Reflectance Spectroscopy (EW-DRS)—Proof of Concept in Ex Vivo Breast Specimens Using Machine Learning. Diagnostics. 13(19). 3076–3076. 6 indexed citations
8.
Ohlsson, Mattias, et al.. (2022). The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer. Breast Cancer Research and Treatment. 194(3). 577–586. 6 indexed citations
9.
Fernö, Mårten, et al.. (2021). St Gallen 2019 guidelines understage the axilla in lobular breast cancer: a population-based study. British journal of surgery. 108(12). 1465–1473. 4 indexed citations
10.
Dahlgren, Malin, Anthony M. George, Christian Brueffer, et al.. (2021). Preexisting Somatic Mutations of Estrogen Receptor Alpha (ESR1) in Early-Stage Primary Breast Cancer. JNCI Cancer Spectrum. 5(2). 16 indexed citations
11.
Brueffer, Christian, Christof Winter, Johan Vallon‐Christersson, et al.. (2020). The mutational landscape of the SCAN ‐B real‐world primary breast cancer transcriptome. EMBO Molecular Medicine. 12(10). e12118–e12118. 42 indexed citations
12.
13.
Vallon‐Christersson, Johan, Jari Häkkinen, Cecilia Hegardt, et al.. (2019). Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. Scientific Reports. 9(1). 12184–12184. 36 indexed citations
14.
Rydén, Lisa, et al.. (2018). Predictive factors for sentinel node metastases in primary invasive breast cancer: a population-based cohort study of 2552 consecutive patients. World Journal of Surgical Oncology. 16(1). 54–54. 13 indexed citations
15.
Welsh, Allison W., Donald R. Lannin, Gregory Young, et al.. (2011). Cytoplasmic Estrogen Receptor in Breast Cancer. Clinical Cancer Research. 18(1). 118–126. 49 indexed citations
16.
Lundgren, Katja, Nicholas P. Tobin, Sophie Lehn, et al.. (2011). Stromal Expression of β-Arrestin-1 Predicts Clinical Outcome and Tamoxifen Response in Breast Cancer. Journal of Molecular Diagnostics. 13(3). 340–351. 23 indexed citations
17.
Larsson, Anna-Maria, Karin Jirström, Erik Fredlund, et al.. (2009). Erythropoietin Receptor Expression and Correlation to Tamoxifen Response and Prognosis in Breast Cancer. Clinical Cancer Research. 15(17). 5552–5559. 21 indexed citations
18.
Rydén, Lisa, Pär‐Ola Bendahl, Thomas Hatschek, et al.. (2009). Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer – A national survey performed at pathology departments in Sweden. Acta Oncologica. 48(6). 860–866. 23 indexed citations
19.
Brennan, Donal J., Karin Jirström, Åsa Kronblad, et al.. (2006). CA IX is an Independent Prognostic Marker in Premenopausal Breast Cancer Patients with One to Three Positive Lymph Nodes and a Putative Marker of Radiation Resistance. Clinical Cancer Research. 12(21). 6421–6431. 107 indexed citations
20.
Dolled‐Filhart, Marisa, Lisa Rydén, Melissa A. Cregger, et al.. (2006). Classification of Breast Cancer Using Genetic Algorithms and Tissue Microarrays. Clinical Cancer Research. 12(21). 6459–6468. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Pär‐Ola Bendahl Breakdown of academic impact, for papers by Ja Seung Koo Breakdown of academic impact, for papers by Dilip D. Giri Breakdown of academic impact, for papers by Daniele Generali Breakdown of academic impact, for papers by Zhi‐Ming Shao Breakdown of academic impact, for papers by A. Bapsi Chakravarthy Breakdown of academic impact, for papers by Hirotaka Iwase Breakdown of academic impact, for papers by Anne F. Schott Breakdown of academic impact, for papers by Helga B. Salvesen Breakdown of academic impact, for papers by Kunwei Shen
Rankless by CCL
2026